Clinical Research Center s.r.o.

The Clinical Research Center s.r.o. is conducting trials that focus on Atopic Dermatitis, evaluating a novel biologic therapy to improve skin health in moderate‑to‑severe patients.

• Placebo‑controlled efficacy assessment of rocatinlimab
• Use of the Validated Investigator’s Global Assessment (vIGA‑AD) as primary endpoint
• Evaluation of the Eczema Area and Severity Index (EASI) scores
• Monotherapy approach in a double‑blind Phase 3 design

These studies aim to demonstrate that the new treatment can significantly reduce disease severity and improve quality of life for participants in Pardubice.

Research at the site targets Heart Failure With Preserved or Mildly Reduced Ejection Fraction combined with Obesity, testing an innovative agent to lower cardiovascular risk.

• Adjunct therapy with maridebart cafraglutide alongside standard care
• Composite endpoint of heart‑failure hospitalization, urgent visits, and cardiovascular death
• Inclusion of participants with BMI ≥ 30 kg/m²
• Phase 3 double‑blind, placebo‑controlled design

The goal is to show that this medication can reduce serious heart‑failure events and improve outcomes for patients with the specified cardiac profile at the Clinical Research Center s.r.o..